Marcia S. Brose, MD, PhD, discusses the SELECT trial, which looks at lenvatinib for patients with 131I-refractory differentiated thyroid cancer.
Lenvatinib has been a very active agent both in the first-line setting and in patients previously treated with other agents, including ceritinib, says Brose.
In both cases, patients treated with lenvatinib are doing well and the response rate is very high. In a phase III trial, 63% of patients experienced a partial response, and a couple of complete responses were also reported.
Brose believes this is clinically significant, especially when patients have very aggressive or symptomatic disease.
Marcia S. Brose, MD, PhD, associate professor of Otorhinolaryngology, Head and Neck Surgery at the Hospital of the University of Pennsylvania, discusses the SELECT trial, which looks at lenvatinib for patients with131I-refractory differentiated thyroid cancer.